Preoperative tumor progression significantly predicts early mortality in patients undergoing cytoreductive hepatectomy for neuroendocrine tumor liver metastases.
- 47% of short-term survivors had preoperative progression compared to 16.6% of long-term survivors (p < 0.001).
- Patients with pancreatic neuroendocrine tumors and progression faced a median overall survival of just 1.8 years (p = 0.042).
Incorporating tumor progression metrics into preoperative evaluations can refine surgical decision-making and improve patient outcomes.
- Tumor growth over 20% and weekly growth over 1.04% were strongly linked to early mortality (p < 0.001).
Journal Article by Podrascanin V, Ammann M (…) Starlinger PP et 10 al. in Eur J Surg Oncol
Copyright © 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.